Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
23 March 2022 | Story André Damons | Photo UFS Photo Archive
Prof Matsabisa
Prof Motlalepula Matsabisa is a professor and Director of Pharmacology at the University of the Free State (UFS)

The Department of Pharmacology at the University of the Free State (UFS) and FARMOVS have teamed up to conduct the first South African Health Products Regulatory Authority (SAHPRA)-approved multicentre controlled clinical trial of a plant-based product, PHELA, on mild to moderate COVID-19 patients.  

According to Prof Motlalepula Matsabisa, professor and Director of Pharmacology at UFS, it is anticipated that the trial will start in early April with each patient being on treatment for 28 days.

“The main purpose of the clinical trial is to confirm that the product can treat COVID-19 and be registered as a medication for this indication. We believe the medication works as an immune modulator to modulate the cytokine storm due to COVID-19 and also restores and normalises the patient’s immune system. We plan to have 250 patients who suffer from mild to moderate COVID-19,” explains Prof Matsabisa. 

This pivotal study, he says, is based on the modification of the World Health Organisation (WHO) Master protocol for clinical trials. The use of FARMOVS, a wholly owned clinical research company of the UFS Bloemfontein campus, for this clinical trial was to implement the collaborative initiatives between UFS and FARMOVS on clinical research, training, and other research projects.

What is PHELA?

Prof Matsabisa, deputy president of the South African Society for Basic and Clinical Pharmacology Society (SASBCP), says the development of PHELA has been under stringent scientific scrutiny for its safety in both preclinical and clinical research. The efficacy of PHELA as both an immune modulator and an anti-SARS-COV-2 has been proven in vitro and in vivo with reproducible results conducted by three independent research institutions and a science council.
The Department of Pharmacology and FARMOVS are collaborating on a number of studies to advance clinical research on African Traditional Medicines (ATM).

On the use of PHELA, Prof Matsabisa explains: “PHELA is a herbal product made of four medicinal plants. Traditionally PHELA has been claimed for use for a historical disease called muyaga, but recently has been scientifically tested and found effective as an immune modulator and benefiting persons with a compromised immune system.
“The PHELA plants are found in most provinces of South Africa and we have cultivated them to control their growth to produce quality raw materials.” 

“The SAHPRA-approved clinical trial will be conducted in the Eastern Cape, Northern Cape and Gauteng. The clinical trial will be conducted by a complement of medical staff and clinicians with vast experience of many active years of clinical trials.
 
“The study, we believe, is a benchmark for all future traditional medicines clinical trial protocols and studies. The studies are expected to start immediately after the product batch manufacturing of the study product, PHELA, is completed and this will be within a month’s time. “A lot of good scientific preclinical safety and efficacy research has gone into the development of the study product for it to reach this stage.

“The efficacy studies have shown convincingly that PHELA is an immune reconstitution product and does have an effect in killing the SARS-COV-2 virus and most of its variants.  PHELA efficacy, therefore, needs to be confirmed through randomised controlled multicentre clinical trials in COVID-19 patients,” Prof Matsabisa says.

Medicinal plants have previously been used to eradicate life-threatening viruses 

Although medicinal plants have been used to combat previous pandemics such as the Spanish flu, avian influenza and others, we still believe rigorous control and efficacy thereof is still to be supported by scientific research and development, says Prof Matsabisa. 

Prof Matsabisa, the current chairperson of the World Health Organisation’s (WHO) Regional Expert Advisory Committee on Traditional Medicines (REACT), adds: “We have better technologies and resources now, which is why we should take the next step in research to promote consumer safety and to offer them effective alternatives. We do the science to aid in building the herbal industry and develop sustained consumer confidence in traditional medicines. 

Africa should lead the way to a healthier future for all
“My vision is for Africa to share our valuable resources with the world by developing, and distributing world-class medicinal solutions. We should develop and strengthen the pharmaceutical local production of well-researched, quality, safe and efficacious African traditional medicines as commercial products. We are more than capable of doing so and now is the time to do it. Numerous discussions have taken place where other African countries will join South Africa in conducting multicentre studies in clinical trials for traditional medicines. 

“We need to develop or create, based on this current collaborative work with partners like FARMOVS, health centres with a strong focus on African medicines, health products and healing, but in a very strong collaborative initiative with other health systems”, concludes Prof Matsabisa.

Prof Matsabisa was recently awarded a Visiting Professorship at the Beijing University of Chinese Medicine (BUCM) in Beijing, China. He was also recommended to Naledi Pandor, Minister of International Relations and Cooperation, to be part of the India, Brazil and South Africa (IBSA) working group in traditional medicine through his participation in the national department of health technical committee on traditional medicines where he has been appointed by the Minister of Health, Dr Joe Phaahla.

News Archive

Inter-country adoptions can offer relief
2009-08-12

 
At the occasion were, in the front: Prof. Hennie Oosthuizen, head of the Department of Criminal and Medical Law, UFS; back: Adv. Mariëtte Reyneke, head of the Unit for Children’s Rights and senior lecturer in the Department of Law of Procedure and Law of Evidence, UFS, Judge of Appeal Belinda van Heerden, and Adv. Beatri Kruger, also from the Unit for Children’s Rights and senior lecturer in the Department of Criminal and Medical Law, UFS.
Photo: Stephen Collett 


Inter-country adoptions must not be taken lightly; however, in some instances it is suitable and can bring relief to a child. These were the words of Katinka Pieterse from Abba Adoptions, which specialises in inter-country adoptions.

She was one of the expert presenters at a recent workshop on inter-country adoptions that was recently presented by the Unit for Children’s rights in the Department of Criminal and Medical Law in the Faculty of Law at the University of the Free State (UFS).

Judge of Appeal Belinda van Heerden, an expert in the field of Child and Family Law, gave an overview as well as a Southern African perspective on this controversial topic. The Hague Convention sets international standards to protect children from the inherent dangers that accompany inter-country adoptions. The South African law must be aligned with these international standards by incorporating specific stipulations as well as the Hague Convention into legislation applicable to children. There must also be acted in the best interest of the child, said Judge van Heerden. The authorities have safety measures in place to protect children from these dangers. The starting point remains that inter-country adoptions are only considered once one cannot find suitable care in the country of origin.

Prof. Sheryl Buske from the Charlotte School of Law, North Carolina in the United States of America in particular emphasised the dangers of human trafficking that can take place when inter-country adoptions do not adhere to international safety standards. She also pointed out new developments such as the role of surrogate mothers and the adoption of embryos.

The workshop was attended by a large variety of role players, varying from academics, lawyers, social workers, non-governmental organisations, law students and representatives from governmental institutions. Consequently, light was shed on the topic from a number of angles which will be of value to the respective role players. Jurists from Lesotho also expressed their gratitude for the insight they received.

The workshop was of great value to the university because it served the community with expert presentations on this new and sensitive topic. The guidelines and pitfalls that were discussed and pointed out at the workshop cleared uncertainties and brought new insight to the different professions and role players in the field. Furthermore, the bond between the academia and practice were developed and strengthened by the establishment of further cooperation between the parties.

Media Release:
Lacea Loader
Deputy Director: Media Liaison
Tel: 051 401 2584
Cell: 083 645 2454
E-mail: loaderl.stg@ufs.ac.za  
11 August 2009

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept